5th Pharmacovigilance Congregation 2013

5th Pharmacovigilance Congregation 2013

20-11-2013 - 20-11-2013 Kohinoor Continental Hotel, Mumbai, IndiaKohinoor Continental Hotel, Mumbai, India

After the successful journey of previous four years of annual Pharmacovigilance conferences, Virtue Insight is proud to announce its 5th Pharmacovigilance 2013 in India.

The emerging markets are rapidly evolving to compete with the standards set by the developed world. Many life sciences companies in India are now focusing strongly on drug safety management and pharmacovigilance. Demand from emerging markets is opening up various opportunities across multiple sectors. Life sciences companies have several compelling reasons to build a presence in emerging markets. By 2020, the size of the global pharmaceutical market is anticipated to grow to $1.3 trillion, with the E7 countries -- Brazil, China, India, Indonesia, Mexico, Russia and Turkey. The rapid induction in the market throws up the challenges of monitoring Adverse Drug Reactions (ADRs) over large population base. All medicines (pharmaceuticals and vaccines) have side effects. Some of these side effects are known, while many are still unknown even though that medicine has been in clinical use for several years.

It is important to monitor both the known and hitherto unknown side effects of medicines in order to determine any new information available in relation to their safety profile. In a vast country like India with a population of over 1.2 billion with vast ethnic variability, different disease prevalence patterns, practice of different systems of medicines, different socioeconomic status, it is important to have a standardized and robust pharmacovigilance and drug safety monitoring programme for the nation. Collecting this information in a systematic manner and analyzing the data to reach a meaningful conclusion on the continued use of these medicines. More clinical research activities being conducted in India, there is an immense need to understand the importance of pharmacovigilance and how it impacts the life cycle of the product. A good pharmacovigilance will easily identify the risk factors in the shortest time so that the harmful effects can be avoided or minimized.

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Mitokyne

mitokyne-logo.jpg

Mitokyne is a Japan-based biotechnology company focused on mitochondria-related drug discovery and development services.

Back to top